Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal

Core Insights - The Portuguese Ministry of Health has approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular event risks in high-risk patients [1] - This approval represents the eighth national reimbursement of VAZKEPA in Europe, enhancing its market presence [1] - The commercialization of VAZKEPA in Portugal will commence on August 1, 2024, providing a new treatment option for patients with established cardiovascular disease [1] Company Overview - Amarin Corporation is focused on innovative pharmaceutical solutions for cardiovascular disease management, with a commitment to addressing cardiovascular risks beyond traditional therapies [1] - The company has a strong intellectual property position for VAZKEPA in Europe, extending until 2039 [1] - Amarin is actively pursuing pricing and reimbursement discussions in other European markets to enhance patient access [1] Market Context - In Portugal, the prevalence of established cardiovascular disease among adults aged 45 to 79 is reported at 10.7% [1] - Cardiovascular disease accounts for over 35,000 annual deaths in Portugal, representing 29% of total mortality in 2017 [1] - The growing prevalence of cardiovascular risk factors underscores the urgent need for effective treatment options in the Portuguese healthcare system [1]